Form 4: MapLight Therapeutics Grants Equity to General Counsel

MapLight Therapeutics, Inc. awarded its General Counsel, Kristopher Hanson, restricted stock units and stock options as part of his compensation.

Summary

• Kristopher Hanson, General Counsel and an Officer of MapLight Therapeutics, Inc. (MPLT), received equity awards on February 5, 2026.
• The awards include 7,730 Restricted Stock Units (RSUs) and options to purchase 31,395 shares of voting common stock.
• The RSU award was granted with a transaction price of $0, representing a contingent right to receive one share of voting common stock per RSU.
• The stock option was granted with an exercise price of $15.70 per share.
• The RSUs will vest 1/4th on January 1, 2027, and 1/16th on each subsequent April 1, July 1, October 1, and January 1, subject to continued service.
• The stock options will vest 1/4th on February 5, 2027, and 1/48th each month thereafter on the same day of the month, also subject to continued service.
• Following these transactions, Kristopher Hanson beneficially owns 191,582 shares of voting common stock directly and 31,395 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with shareholder value over the long term.

Positives

• Aligns management incentives with shareholder interests through equity awards, encouraging long-term performance.
• Provides long-term retention incentives for a key executive, Kristopher Hanson, ensuring continuity in leadership.
• The awards are part of standard executive compensation practices, reflecting a structured approach to talent management.

Negatives

• Potential for future minor dilution for existing shareholders upon the vesting and exercise of the RSUs and stock options.

Future Outlook

The vesting schedules for both the RSUs and stock options extend several years into the future, indicating an expectation of Kristopher Hanson's continued service to MapLight Therapeutics, Inc. and a long-term incentive structure designed to retain key talent.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the General Counsel are a standard practice in the biotechnology and pharmaceutical industries. These awards are designed to attract, retain, and motivate top talent by aligning their financial interests with the long-term performance of the company and its shareholders. The structure of these awards, with multi-year vesting schedules, reinforces a commitment to long-term value creation.

Stakeholder Impact

• **Shareholders:** Potential for minor future dilution upon the vesting and exercise of equity awards, but also increased alignment of executive interests with long-term shareholder value and company performance.
• **Employees:** Reflects standard compensation practices for key personnel, potentially signaling stability in executive retention and a commitment to long-term incentives.

Next Steps

• Continued service of Kristopher Hanson to meet the vesting conditions for both RSU and stock option awards.
• First vesting of 1/4th of the RSU award on January 1, 2027.
• First vesting of 1/4th of the stock option award on February 5, 2027.
• Subsequent quarterly vesting of RSUs and monthly vesting of stock options as per the defined schedules.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Kristopher Hanson, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Grant, General Counsel